Breaking News

Forest Wins Lexapro Patent Fight

The U.S. District Court for the District of Delaware has determined that Forest Laboratories‘ patent covering escitalopram, the active ingredient in Lexapro, is both valid, enforceable and infringed by Ivax/Teva’s proposed generic product. The ruling confirms patent rights for Lexapro, which expire in March 2012, for Forest and its partner H. Lundbeck A/S of Denmark.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters